Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health
Unveiling the Power of Epigenetics in Male Fertility: A New Horizon Beyond Semen Analysis
Unveiling the Power of Epigenetics in Male Fertility: A New Horizon Beyond Semen Analysis
Inherent Biosciences, Inc. Advances Fertility Solutions With Transformative Grant Funding From the NIH
A Leap Forward for Patients, a Promising Opportunity for Investors, and a Revolutionary Tool for Physicians
Inherent Biosciences Partners With Posterity Health to Accelerate the Path to Parenthood by Elevating the Standard of Care in Male Reproductive Health
Inherent Biosciences has teamed up with Posterity Health, the only virtual Male Fertility Center of Excellence, to address male fertility
Inherent Biosciences awarded NIH SBIR Phase I Grant to commercialize innovative diagnosis of non-obstructive azoospermia (the most severe form of sperm dysfunction)
Inherent Biosciences announced an award from the National Institute of Child Health and Human Development’s Fertility and Infertility Branch to develop a clinical assay for improved diagnosis of non-obstructive azoospermia (NOA).
Inherent Biosciences Launches Path Fertility – Epigenetic Sperm Quality Test (SpermQT)
SpermQT analyzes the molecular function of sperm and is 6x more predictive of fertility potential than standard semen analysis.
